Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$70.07|
|52 Week High||US$39.10|
|52 Week Low||US$84.97|
|1 Month Change||15.63%|
|3 Month Change||6.34%|
|1 Year Change||41.41%|
|3 Year Change||455.67%|
|5 Year Change||3,438.89%|
|Change since IPO||-36.87%|
Recent News & Updates
|CYRX||US Medical Equipment||US Market|
Return vs Industry: CYRX exceeded the US Medical Equipment industry which returned 32.6% over the past year.
Return vs Market: CYRX exceeded the US Market which returned 32.8% over the past year.
Stable Share Price: CYRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: CYRX's weekly volatility (6%) has been stable over the past year.
About the Company
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle; and Cryoport Express Advanced Therapy Shippers that provides verification processes to biopharma companies. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems.
Cryoport Fundamentals Summary
|CYRX fundamental statistics|
Is CYRX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CYRX income statement (TTM)|
|Cost of Revenue||US$93.11m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.70|
|Net Profit Margin||-46.39%|
How did CYRX perform over the long term?See historical performance and comparison
Is Cryoport undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: CYRX ($70.07) is trading above our estimate of fair value ($21.53)
Significantly Below Fair Value: CYRX is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CYRX is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: CYRX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CYRX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CYRX is overvalued based on its PB Ratio (5x) compared to the US Medical Equipment industry average (4.7x).
How is Cryoport forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CYRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CYRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CYRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CYRX's revenue (23.5% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: CYRX's revenue (23.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CYRX's Return on Equity is forecast to be low in 3 years time (2.4%).
How has Cryoport performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CYRX is currently unprofitable.
Growing Profit Margin: CYRX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CYRX is unprofitable, and losses have increased over the past 5 years at a rate of 47% per year.
Accelerating Growth: Unable to compare CYRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CYRX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (40.5%).
Return on Equity
High ROE: CYRX has a negative Return on Equity (-4.92%), as it is currently unprofitable.
How is Cryoport's financial position?
Financial Position Analysis
Short Term Liabilities: CYRX's short term assets ($411.8M) exceed its short term liabilities ($38.2M).
Long Term Liabilities: CYRX's short term assets ($411.8M) exceed its long term liabilities ($139.1M).
Debt to Equity History and Analysis
Debt Level: CYRX's debt to equity ratio (17.9%) is considered satisfactory.
Reducing Debt: CYRX's debt to equity ratio has increased from 17% to 17.9% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CYRX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CYRX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Cryoport current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CYRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CYRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CYRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CYRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CYRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jerry Shelton (76 yo)
Mr. Jerrell W. Shelton, also known as Jerry, has been the Chief Executive Officer and President of CryoPort, Inc. since November 5, 2012 and has been its Chairman of the Board since October 2015. Mr. Shelt...
CEO Compensation Analysis
Compensation vs Market: Jerry's total compensation ($USD5.48M) is about average for companies of similar size in the US market ($USD5.22M).
Compensation vs Earnings: Jerry's compensation has increased whilst the company is unprofitable.
Experienced Management: CYRX's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Experienced Board: CYRX's board of directors are considered experienced (6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.7%.
Cryoport, Inc.'s employee growth, exchange listings and data sources
- Name: Cryoport, Inc.
- Ticker: CYRX
- Exchange: NasdaqCM
- Founded: 1999
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$3.225b
- Shares outstanding: 46.02m
- Website: https://www.cryoport.com
Number of Employees
- Cryoport, Inc.
- 112 Westwood Place
- Suite 350
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/27 23:02|
|End of Day Share Price||2021/09/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.